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PERSPECTIVES IN CLINICAL NEPHROLOGY
Is adsorption an important characteristic of dialysis membranes?
Since the 1960s, cuprophane membranes (cellulose-based) have
been widely used for hemodialysis. However, it has become
evident over the years that the interaction of blood with cu-
prophane leads to a rapid and massive complement activation
with leukopenia, and to the release of cytokines which may be
detrimental to uremic patients [11. This led to the concept of
cuprophane as a "bio-incompatible" membrane (BICM). Since
the 1980s new synthetic membranes have been developed such as
polysulfone, polyaciylonitrile (PAN/AN69 and other PAN), poly-
amide, and polymethylmethacrylate (PMMA), which have been
shown not to activate complement (or to a lesser extent than
cuprophane) and are generally considered biocompatible mem-
branes (BCM). Although the complement pathway has been
studied extensively, it is worth emphasizing that other humoral
pathways (coagulation, contact-phase) and cellular mechanisms
can also be activated during dialysis, thus rendering the definition
of "biocompatibility" more complex than previously expected [1,
2]. For example, the PANIAN69 membrane, usually regarded as a
BCM, may also be judged as a BICM for patients on angiotensin-
converting enzyme inhibitors, since hypersensitivity reactions due
to bradykinin release have been reported [1, 3]. Nevertheless, in
two recent studies the term "BCM" was used to describe the use
of PAN/AN69 and PMMA membranes, and importantly their use
was shown to be beneficial for the patients [4, 51. Hakim recently
defined the "BCM" as "one that elicits the least amount of
inflammatory response in patients exposed to it" [1]. In the future,
it may be that an important factor—if not the most important—in
defining "biocompatibility" will be the impact that dialysis mem-
branes have on patient's morbidity and mortality [2]. BCM would
be those membranes proven to be beneficial for the patients, and
BICM those leading to deleterious consequences or outcomes.
In the past the concept of hemodialysis has focused on the
processes of diffusion and mass transfer across a semipermeable
membrane. In recent years, several reports have pointed out that
adsorption (that is, binding to the membrane) of some low-
molecular weight proteins or peptides (LMWP) on certain types
of dialysis membranes represents an additional and important
mechanism of clearance during hemodialysis. Here we review
examples of LMWP adsorption by dialysis membranes that may
be important in terms of biocompatibility, and which may influ-
ence the morbidity and mortality of patients requiring dialysis.
Other important characteristics such as the larger pore size and
higher ultrafiltration coefficients of some new synthetic mem-
branes will not be discussed.
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Does the membrane influence the outcome of the patients?
First it seems important to review the existing data indicating
that the prefential use of some dialysis membranes may be
clinically relevant. A number of studies have shown that BCM
may affect the outcome of the patients, both in the acute and
chronic hemodialysis setting.
Acute renal failure
In 1994, the results of two prospective randomized studies
showed that the survival rate of critically ill patients, and their rate
of recovery from acute renal failure (ARF), were significantly
higher when two BCM (PAN/AN69 and PMMA, respectively)
were compared to the BICM cuprophane [4, 5]. For the first time,
data were provided indicating that different membranes could
result in different patient's outcome. These results are of impor-
tance for critically ill patients with ARF due to acute tubular
necrosis, since the mortality rate in most series has remained
around 60% despite an improvement in the general management
of these patients. Moreover, in a recent multicenter study com-
paring PMMA and cuprophane membranes, similar results were
found, that is, a significantly better survival and recovery from
ARF with PMMA in the patients with non-oliguria before initia-
tion of dialysis [6]. Thus, these interesting data suggest that the
the use of BCM seems to be justified since it may be of benefit for
patients with ARF. However, as pointed out recently, many
variables other than the membrane can affect the outcome of
patients with ARF, and our current criteria available to random-
ize evenly critically ill patients with ARF are not optimal [7].
Therefore, a risk of bias in the selection or management of these
patients exists, which may affect the conclusions of such studies.
Further work is necessary to confirm the favorable initial results
achieved with the use of BCM in ARF.
How could the dialysis membrane affect the recovery from
ARF? In 1991, Schulman et al reported that complement activa-
tion may retard resolution of ischemic ARF in the rat. These
authors elegantly showed that cuprophane membranes and zymo-
san, two known complement activators, significantly delayed
recovery from ARF as compared to control or PAN/AN69
(non-complement activating membrane) exposed animals [8].
Histological examination of the kidneys revealed that cu-
prophane-exposed animals had significantly more neutrophil in-
filtration in the renal parenchyma. The important role of neutro-
phils in the pathogenesis of ischemic ARF has been demonstrated
recently. In the rat model, blockade of ICAM-mediated neutro-
phil extravasation protected against ischemic ARF, even when
anti-ICAM antibody was administered two hours after the isch-
emic insult [9]. Interestingly, complement activation by cu-
prophane membranes has been shown to up-regulate adhesion
molecules on granulocytes [10, 11]. Thus, stimuli that activate
complement and granulocytes may be detrimental in a freshly
injured kidney with ARF, thereby providing an explanation for
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the significantly poorer results observed with cuprophane mem-
branes in the recent clinical trials. Other additional and unknown
mechanisms may play a role in the best results observed with
PAN/AN69 and PMMA membranes. This may be particularly
true for the PMMA membrane which still has moderate comple-
ment activating properties, however, significantly lower than
cuprophane [12, 13].
Chronic renal failure
There is no definitive evidence that patients on regular hemo-
dialysis using BCM have a lower morbidity or mortality as
compared to patients dialyzed with BICM. This is mainly due to
the lack of well designed, prospective and randomized studies that
address these important issues. However, as pointed out by
Hakim, several lines of evidence indicate that the chronic use of
BICM may have adverse consequences in the patients, ranging
from acute hemodynamic instability, increased incidence of infec-
tions to the development of dialysis-related amyloidosis [1]. For
example, several studies have shown a higher incidence of acute
symptoms ("first use syndrome") in patients dialyzed with BICM
(cellulosic, new), as compared to patients dialyzed with similar but
reused membranes, which have an impaired ability to activate
complement [14—16]. These reactions may be particularly detri-
mental for patients with underlying cardiovascular disease, a
common condition in end-stage renal disease (ESRD). Moreover,
in a large retrospective multicenter study of chronically dialyzed
patients, van Ypersele de Strihou found that patients treated with
PAN/AN69 (as compared to cellulosic membranes) had less
frequently signs of dialysis-related amyloidosis [17]. In another
retrospective study of 352 patients on hemodialysis on PAN!
AN69, it was noted that the observed mortality rate over a 10 year
period was significantly lower than that expected from the U.S.
Renal Data System mortality projections [181. Despite their
retrospective nature, the results of such large studies point
towards a potential important role of membrane biocompatibility.
On the other hand, Charra et al found that excellent patient
survival can be obtained with cuprophane membranes, if a higher
dose of dialysis is delivered (24 hr!week, Kt/V of 1.67) with an
optimal control of blood pressure [19]. Furthermore, in a recent
study, the Bergamo group did not show any difference in mortality
between cellulosic and high-flux synthetic polysulfone membranes
[20]. Thus, at least under certain conditions, chronic exposure to
BICM appears not to be harmful for the patients.
Adsorption by dialysis membranes
Is there a nonspecific adsorption?
To try to define which adsorptive properties are specific to a
given membrane is probably irrelevant for practical purposes. It
may be more important to focus the discussion on the conse-
quences that protein adsorption onto the membranes may have in
improving biocompatibility. For example, reused cellulosic BICM
have a low complement activating capacity, a characteristic that
may be beneficial for the patients [21]. However, direct demon-
stration that dialyzer reuse improves patient survival is lacking. It
has been shown that during the normal use of a new cellulosic
dialyzer, coating of the membrane with a protein film occurs,
which results in the significantly reduced C3a and C5a production
of reused cellulosic dialyzers [2]. Proteins coated on the mem-
brane surface include albumin and C3 fragments, particularly C3b
(covalently-bound) and C3c,C3d (noncovalently-bound) [21—23].
It should be noted that reuse techniques which employ hypochlo-
rite (in addition to formalin) to rinse the dialyzers remove the
membrane coated protein, therefore abrogating the potential
benefits of reuse [241.
Synthetic membranes, in particular hydrophobic membranes
(PAN!AN69, PMMA, polysulfone, polyamide), adsorb more pro-
teins than cellulosic membranes [1]. However, there are few data
available comparing the quality and quantity of proteins adsorbed
to these different membranes. A membrane which has been
studied extensively is the PAN!AN69 membrane (copolymer of
polyacrylonitrile and methallyl sulfonate), which appears to have
very potent adsorptive properties. In addition to albumin, this
membrane has been shown to efficiently adsorb a variety of
proteins such as IgG, fibrinogen, interleukin 1 (IL-I), 132-micro-
globulin, Clq, C3, C5, lysozyme, cytochrome c, and PTH (car-
boxy-terminal fragments and intact hormone) [25—27]. Removal
of carboxy-terminal fragments by adsorption may be beneficial for
patients on hemodialysis, since these fragments have been pro-
posed to play a role in the pathogenesis of renal osteodystrophy
(adynamic form) [28]. It should be noted that adsorption of
proteins is not necessarily beneficial: for instance, adsorbed
fibrinogen may enhance platelet adhesion and contribute to
clotting of the dialyzer [29].
An interesting observation was made by Amadori et al several
years ago. In vitro, the PAN!AN69 membrane was shown to
adsorb complement activity of normal human serum, but no C3
activation could be detected [26]. Thus it was hypothetized that
essential complement components of the alternative pathway
were adsorbed and!or inactivated by this membrane [25—26].
Moreover, in dialysis circuits, placement of a PAN/AN69 dialyzer
proximal to a cuprophane dialyzer significantly reduced comple-
ment activation induced by cuprophane, which again indicated
that PAN!AN69 removed a plasma component essential for C3
activation [30]. Subsequently, complement factor D was identified
as being the culprit.
Complement factor D, complement activation, and cytokines
Factor D is the essential, rate-limiting enzyme of the alternative
pathway (AP) of complement activation. Its molecular wt is 23
kD, and its plasma concentration is increased approximately
10-fold in patients with ESRD [31]. Indeed, like many other
LMWP, factor D accumulates in renal failure because of an
impaired elimination by the kidneys. This high level of function-
ally active factor D is directly responsible for enhanced activation
of the AP in the plasma of ESRD patients [32]. This situation is
particularly unfavorable for hemodialysis patients since many
membranes trigger complement activation by the AP [33]. It has
been well demonstrated that cuprophane membranes (and cellu-
losic membranes in general) directly activate the AP, and that this
activation can lead to anaphylactoid reactions [16]. Furthermore,
complement activation, by the release of some biologically active
fragments such as C3a, C5a, and C5b-9, can directly induce the
release of interleukin 1 (IL-i), tumor necrosis factor (TNF) and
interleukin 6 (IL-6) by monocytes [34—36]. For patients undergo-
ing hemodialysis, chronic complement activation as well as
chronic cytokine production induced by cellulosic membranes
may be associated with enhanced susceptibility to infection, 13-2
microglobulin amyloidosis and increased protein catabolic rate [1,
37, 38]. Although other factors may play a role in cytokine
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production during hemodialysis (such as endotoxin in dialysate or
direct activation of the monocytes by the membranes), it seems
likely that complement activation plays the major role. First,
cuprophane membranes, which induce the strongest complement
activation, are also associated with the highest cytokine induction.
Secondly, Schindler et a! found a very significant correlation
between C5a production and IL-113 gene expression in peripheral
blood mononuclear cells (PBMC) during dialysis with cuprophane
membranes. These authors elegantly demonstrated that blocking
C5a reduced the increase in IL-113 mRNA expression during
hemodialysis by more than 80% [39]. Furthermore, in a recent
study analyzing the production of TNF-a by cuprophane dialysis
membranes, no cytokine production could be attributed to the
presence of endotoxin in the dialysate [40]. It appears that both
C5a and C5b-9 generation may be critical factors in determining
transcription and translation of cytokines by monocytes [35, 36].
All these data indicate that an effective blockade of the AP of
complement should directly result in a decrease or absence of
cytokine release.
Could adsorption of factor D on dialysis membranes inhibit AP
activation? In vitro and in vivo studies using specific blocking
antibodies against factor D have shown that blockade of factor D
function achieves blockade of AP activation [41]. Recently it has
been shown that both PAN/AN69 and PMMA membranes re-
move large amounts of factor D, and this removal is mainly due to
adsorption [42, 43]. At the end of regular hemodialysis sessions,
there is a substantial decrease of circulating factor D in blood, in
the order of 80% with PAN/AN69 and 50% with PMMA mem-
branes, contrasting with a less than 10% decrease with cellulose
acetate membranes. By measuring the concentrations of factor D
in dialysis fluid samples, it has been calculated that more than
98% and 85% of factor D removal occurs by adsorption using
PAN/AN69 and large pore PMMA membranes, respectively,
whereas no adsorption occurs onto cellulosic membranes [42, 43].
More interestingly, however, is the fact that factor D bound to
these BCM is enzymatically inactive, thus resulting in complement
inhibition at the blood/membrane interface. These fine interac-
tions indicate that some membranes have the potential to inhibit
AP activation, and therefore diminish or suppress subsequent
cytokine release. It is of note, for example, that PAN/AN69 does
not induce any IL-13 gene expression, nor IL-6 or TNF-a
production during regular chronic hemodialysis [36, 39, 40]. More
work is required to determine to what extent other synthetic
membranes may also remove factor D, either by adsorption
and/or mass transfer.
The use of highly adsorptive membranes which have the
potential to down-regulate the "complement-cytokine connec-
tion" may also be beneficial in critically ill patients with ARF, and
may accelerate the recovery from ARF [4—6, 8]. Moreover, in
some patients (such as with sepsis or ARDS), a state of enhanced
complement activation with high levels of circulating cytokines is
likely to be present, even before the start of dialysis [44]. The
PAN/AN69 membrane has been shown to efficiently adsorb
anaphylatoxins (C3a, C5a), bradykinin, endotoxins, and cytokines
(IL-i, TNF), that is, all circulating factors which play a role in the
pathophysiology of sepsis [38, 44—48]. Since cytokines are LMWP
with molecular weights ranging from 10 to 55 kD, they may be
more effectively removed by adsorption rather than by mass
transfer across the membrane [481. There is still a debate whether
the presence of high levels of cytokines such as TNF-cw may be
beneficial or harmful in sepsis. The results of a recent random-
ized, double-blind, multicenter clinical trial suggest that blockade
of TNF reduces mortality in patients with septic shock, without
increasing the incidence of infections [491. Thus, removal of TNF
by adsorption onto dialysis membranes might well be beneficial in
septic states. Of note, the possible membrane adsorption of
naturally occurring inhibitors of cytokines should also be studied,
since it may influence the resulting cytokine bioactivity [50].
Finally, it should be emphasized that modalities such as continu-
ous hemofiltration with highly adsorptive membranes have the
potential to simultaneously down-regulate different biological
systems in the plasma of patients with ARF. Although this
remains to be studied, if it turns out to be beneficial for the
patients (such as in sepsis with multiorgan failure), the dialysis
membrane might be viewed as a drug.
132-microglobulin
In 1985, a new form of amyloidosis affecting uremic patients on
long-term hemodialysis was described, the so-called "dialysis-
related amyloidosis" (DRA) [38]. The protein associated with
these amyloid deposits has been identified as 2-microglobulin
(132m), a 12 kD globular protein expressed on the surface of all
nucleated cells as a part of the human class I major histocompat-
ibility complex. As a result of shedding from cells, /32m appears in
its free form in extracellular fluids, and its normal serum concen-
tration ranges from Ito 3 mg/liter [51]. Serum levels as high as 40
to 60 mg/liter have been reported in patients on regular hemodi-
alysis. Although the precise mechanisms of amyloidogenesis are
not completely understood, it must be noted that "uremic con-
centrations" of /32m are a prerequisite for the development of
DRA. It has been shown that the synthesis and release of 2m are
regulated by cytokines such as TNF, interleukin 2, and interferon
gamma and alpha. Thus BICM may further increase f32m produc-
tion and accumulation in patients on regular hemodialysis. This is
supported by studies which demonstrated an increased 132m
mRNA expression and production in lymphocytes and mononu-
clear cells cultured at the end of regular dialysis sessions with
cellulosic membranes [38].
Because of potentially severe incapacitating consequences of
DRA (carpal tunnel syndrome, painful bone cysts, and spondy-
larthropathy), there has been a particular interest in the study of
132m removal by different dialysis membranes. Since 1986, several
investigations pointed out that PAN/AN69 membranes may pre-
vent DRA [52—54]. Subsequent studies have shown that removal
of /32m by these membranes is substantial, with a weekly removal
of 400 to 600 mg of /32m, whereas cuprophane membranes do not
eliminate I32m [38]. Interestingly, adsorption of f32m on the
PAN/AN69 membrane as well as transfer of the protein across the
membrane to the dialysate have been shown to represent signifi-
cant mechanisms of j32m removal [55]. During a four-hour
hemodialysis session, it was calculated that PAN/AN69 mem-
branes remove 2m mainly by adsorption (60%), the rest being
handled by transmembranous transport [561. Studies with other
membranes have likewise emphasized the role of adsorption in
132m removal. In particular, BK-PMMA membranes (large pore
PMMA) possess high adsorptive properties for /32m [571. Re-
moval of 2m by BK-PMMA membranes has been shown to occur
mainly (more than 90%) by adsorption, and the total elimination
of f32m is similar to that obtained with the use of PAN/AN69
membranes [57, 58]. Other membranes such as polysulfone or
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polyamide have also been shown to possess adsorptive properties
for f32m, although less than that of PAN/AN69 [59]. For example,
adsorption of f32m to polysulfone membranes has been shown to
represent less than 20% of the total 2m removal, which occurs
mainly by diffusion/convection [56]. Thus, adsorption appears to
be an important mechanism for 132m removal by some dialysis
membranes, in addition to transmembranous transport of the
protein that occurs as well. It should be noted that, although the
removal of 2m with membranes such as BK-PMMA or PAN!
AN69 is important and permits a decrease of serum levels by 50%
at the end of a normal dialysis session, this is still insufficient to
compensate the continuous synthesis of f32m, which is approxi-
mately 1500 mg per week [38, 57]. Nevertheless, a significant
removal of /32m during each dialysis session may slow the contin-
uous accumulation of 2m in uremic patients.
Overall, it appears that the potential beneficial effects of
synthetic membranes in preventing DRA may be predominantly
related to an increased removal of 2m, rather than to a decreased
synthesis of 2m by mononuclear cells. In addition, highly adsorp-
tive membranes, by limiting repeated complement activation,
cytokine production or protease release, may also interfere with
essential steps of f32m amyloidogenesis (such as j32m polymeriza-
tion or proteolysis), providing a basis for the decrease incidence of
DRA in patients dialyzed with such membranes [17, 38].
Conclusion
The adsorptive properties of some dialysis membranes may be
important in defining their biocompatibility. Adsorption/inhibi-
tion of factor D with blockade of the AP of complement and
cytokine release, endotoxin and cytokine adsorption, and removal
of 132m are all examples that may contribute to a decrease in
morbidity and mortality of patients undergoing both acute and
chronic hemodialysis. More long-term, carefully designed pro-
spective studies are needed to compare "biocompatible mem-
branes" to cellulosic membranes, and perhaps more importantly,
the subgroup of highly adsorptive membranes should be particu-
larly analyzed. It may be that not all biocompatible membranes
are equal, and that those membranes with high adsorptive capa-
bility may be more biocompatible than others. In intensive care
units, in view of the poor outcome of critically ill patients with
multiorgan failure, studies should also be continued to confirm
and to determine which membranes should be preferentially used
to treat these patients [60].
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